We are pleased to announce that Dr. Jörg Taubel, will be one of the faculty members at the upcoming course tailored for postgraduates in life sciences interested in early clinical development of medicinal products.

This comprehensive course consists of two parts, spanning several days, providing an in-depth overview of Human Pharmacology and Translational Medicine. The curriculum covers essential topics from non-clinical pharmacology and toxicology to first-in-man studies and proof-of-concept clinical trials.

To find out more, click here:

Latest news

Richmond enrols first patients in Verve Therapeutic’s Heart-2 trial - pioneering a new approach to cardiovascular disease

June 27, 2024
Richmond enrols and doses the first patient in a clinical trial aimed at transforming the care of cardiovascular disease with single treatment gene-editing medicines.
Read more

A first of a kind trial in the fight against malaria

June 12, 2024
Richmond successfully recruits and enrols adults of sub-Saharan ancestry who all complete a first of its kind trial in the treatment of malaria.
Read more


AHA Hypertension Scientific Sessions 2024

5 - 8 September 2024
Dr. Jörg Taubel, CEO of Richmond Pharmacology, will be attending the Hypertension 2024 Scientific Sessions
View event